An analytics firm Trilliant Health analysis revealed a significant surge in prescriptions for diabetes and obesity drugs like Ozempic and Wegovy during the
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee meeting reviewing BrainStorm Cell Therapeutics Inc's (NASDAQ: BCLI) NurOwn application voted that NurOwn did not demonstrate substantial evidence of effectiveness for treatment of
Stifel initiated coverage on Nuvalent Inc (NASDAQ: NUVL), recognizing that adopting a bullish stance in anticipation of Phase 1 cancer drug data, mainly when derived from heavily pretreated patients, has proven unprofitable for approximately two years.
The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product.
Seelos Therapeutics Inc (NASDAQ: SEEL) announced preclinical data from an in vivo study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) in an aggressive Alzheimer's disease
In a significant development, the FDA has updated the labeling for Novo Nordisk A/S's (NYSE: NVO) Ozempic, a diabetes drug known for its weight loss side effect, to include warnings about reports of blocked intestines